Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Adamantane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adamantane SCHEMBL28003802 | 1.00 | CYP2C9 (0.38) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL317246 | 0.94 | CYP2C9 (0.40) | CYP2C9LMNA | |
| Adamantane SCHEMBL18065809 | 0.94 | CYP2C9 (0.40) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL28551331 | 0.94 | CYP2C9 (0.40) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL8848421 | 0.88 | CYP2C9 (0.43) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL192523 | 0.88 | CYP2C9 (0.43) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL870112 | 0.88 | CYP2C9 (0.43) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL913610 | 0.88 | CYP2C9 (0.43) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL30536640 | 0.88 | CYP2C9 (0.43) | CYP2C9LMNAPOLBTHRBBLM | |
| Adamantane SCHEMBL28257325 | 0.88 | CYP2C9 (0.43) | CYP2C9LMNAPOLBTHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117224491-A | Rimantadine hydrochloride anhydrous swallow granule and preparation method thereof | 北京诺康达医药科技股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-112076174-B | Rimantadine hydrochloride tablet and preparation method thereof | 四川省百草生物药业有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-8476037-B2 | Method for screening of antiviral agents | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20030176494-A1 | Novel coumarin and chromene compounds and methods of preparation and use thereof for treating or preventing viral infections | ADVANCED LIFE SCIENCES, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003070159-A2 | NOVEL COUMARIN AND CHROMENE COMPOUNDS AND METHODS OF TREATING OR PREVENTING VIRAL INFECTIONS | SARAWAK MEDICHEM PHARMACEUTICALS (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-0833631-B1 | ROBUSTAFLAVONE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | ADVANCED LIFE SCIENCES INC (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1245230-A2 | Amentoflavone as an antiviral agent | Advanced Life Sciences Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6420571-B2 | Methods for preparing antiviral calanolide compounds | SARAWAK MEDICHEM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | ADVANCED LIFE SCIENCES, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6399654-B1 | ADMINISTERING MIXTURE OF VIRICIDE AND BIOFLAVANOID | ADVANCED LIFE SCIENCES, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6369241-B1 | MULTISTAGE REACTION OF KETOESTER WITH 1,3,5-TRIHYDROXYBENZENE TO PRODUCE DIHYDROXYOXOCOUMARONE, COUPLING AND CYCLIZATION | SARAWAK MEDICHEM PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020013478-A1 | Calanolide analogues and methods of their use | SARAWAK MEDICHEM PHARMACEUTICALS,INC. | 2002-01-31 | — | — | US | disclosed |
| US-20020013480-A1 | Methods for preparing antiviral calanolide compounds | SARAWAK MEDICHEM PHARMACEUTICALS, INC. | 2002-01-31 | — | — | US | disclosed |
| US-6277879-B1 | VIRICIDES | SARAWAK MEDICHEM PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| US-5948918-A | PLANT EXTRACTS | MEDICHEM RESEARCH, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1998046238-A1 | BIFLAVINOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS, ALONE OR IN COMBINATION WITH AT LEAST ONE KNOWN ANTIVIRAL AGENT | MEDICHEM RESEARCH, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5773462-A | INFLUENZA THERAPY | MEDICHEM RESEARCH, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | HK2, GYS2, HK1 | CYP2C9 2749/4885LMNA 4071/4885POLB 3037/4885 |
| US-20020013480-A1 | Methods for preparing antiviral calanolide compounds | ZC3HAV1, ZC3HAV1L, CYP8B1 | CYP2C9 393/4885LMNA 3131/4885POLB 35/4885 |
| US-20030176494-A1 | Novel coumarin and chromene compounds and methods of preparation and use thereof for treating or preventing viral infections | HAVCR2, PROC, CTRC | CYP2C9 68/4885LMNA 159/4885POLB 3373/4885 |
| US-20020013478-A1 | Calanolide analogues and methods of their use | HAVCR2, ZC3HAV1, CYP51A1 | CYP2C9 1489/4885LMNA 2496/4885POLB 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.